BioView
BioView develops and markets automated cell imaging and analysis systems for clinical cytogenetic, pathology, and oncology research laboratories, combining motorized microscopy, proprietary AI/deep-learning algorithms, and a review software platform, distributed globally through Abbott Molecular and direct US sales.
- Company typePublic
- Founded2000
- HeadquartersBillerica, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What BioView does
BioView Ltd., founded in 2000 and headquartered in Rehovot, Israel (with a wholly-owned US subsidiary, BioView Inc., in Billerica, Massachusetts), develops, manufactures, and markets automated cell imaging and analysis solutions for clinical and research laboratories. The company is publicly traded on the Tel Aviv Stock Exchange under the ticker BIOV. Its portfolio spans two product families: scanning systems (Accord, Accord Plus, Allegro Plus, Duet-3, Encore, and the DeNovo CTC Scanner) that combine motorized fluorescent and bright-field microscopes, high-resolution cameras, and proprietary image-processing algorithms, and a review workstation line (Solo, Solo Touch, and SoloWeb) that supports local and remote analysis and reporting. Core applications include automated FISH scanning (HER2, ALK, UroVysion, and other oncology probes), AI-driven karyotype analysis with deep-learning-based metaphase finding and chromosome classification, and circulating tumor cell (CTC) detection and characterization for liquid biopsy workflows. BioView has secured FDA, CE, Chinese NMPA, Korean KFDA, Australian TGA, Taiwan FDA, and Thai FDA approvals for its systems.
The company's business model is built on a mix of capital equipment sales (scanning systems), one-time software licenses for application-specific algorithms, recurring revenue from the SoloWeb subscription platform, and service and support contracts. Go-to-market is hybrid: in the United States, Canada, and South America BioView sells directly through BioView Inc. to clinical cytogenetic, pathology, and oncology research laboratories; outside the Americas, Abbott Molecular serves as the exclusive worldwide distributor under a relationship established in 2013 and expanded with a 2014 joint development agreement for FISH probe automation. The company also maintains regional distributors in Australia/New Zealand (Diagnostic Solutions) and Brazil (CITOGEM), and has built a co-development partnership ecosystem with CTC enrichment players including ANGLE plc, Capio Biosciences, Vortex Biosciences, Abnova, and RUBYnanomed. Customer concentration sits in enterprise hospital and reference laboratories (e.g., Sheba Hospital, Ichilov Hospital, Cancer Genetics Inc., HSL Advanced Diagnostics), and BioView actively participates in major scientific conferences (ACMG, USCAP, AACR, ESHG, ASHG, AMP) to support clinical credibility.
BioView firmographics
Firmographics- Name
- BioView
- Legal name
- BioView Ltd.
- Website
- https://bioview.com
- Company type
- Public
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- BioView develops and markets automated cell imaging and analysis systems for clinical cytogenetic, pathology, and oncology research laboratories, combining motorized microscopy, proprietary AI/deep-learning algorithms, and a review software platform, distributed globally through Abbott Molecular and direct US sales.
- Ownership category
- akta.pro rank
BioView industry classification
Industry- Product category
- Automated Cell Imaging and Analysis Systems
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE)
- akta.pro secondary industries
- Flow Cytometry & Cellular Analysis Diagnostics (HLAHAAAF), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)
Keywords
Where BioView is headquartered
LocationHeadquarters
- HQ city
- Billerica
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
BioView business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- Imaging System Hardware Sales: Sale of automated scanning microscopes and imaging platforms including Accord, Allegro Plus, Duet-3, Encore, and DeNovo systems with varying capacity levels.
- Software Applications: Application-specific software for FISH, Karyotype, CTC, and pathology analysis with dedicated algorithms for different probe types and sample preparations.
- Review Workstation Software: Solo product line including Solo Workstation, Solo Touch, and SoloWeb for remote review, analysis and reporting.
- Service and Support: Technical support services for US, Canada, South America, Europe, Middle East, Africa and Asia markets.
Go-to-market motion2 records
Distribution channels5 records
Marketing channels6 records
BioView product offering
Product offeringCore offering
BioView develops, manufactures, and markets automated cell imaging and analysis systems that combine motorized fluorescent and bright-field microscopes with high-resolution cameras and AI/deep learning software for FISH (fluorescence in situ hybridization), karyotype, and circulating tumor cell (CTC) analysis. The product line spans semi-automatic single-slide scanners (Accord), mid- to high-throughput multi-slide platforms (Allegro Plus, Duet-3, Encore), a dedicated CTC liquid biopsy scanner (DeNovo), and review workstations (Solo, Solo Touch, SoloWeb) used by clinical cytogenetic, pathology, oncology, and research laboratories worldwide.
Product overview
BioView develops, manufactures and markets innovative automated cell imaging and analysis solutions for use in cytology, cytogenetic, pathology clinical and research laboratories. The product portfolio consists of scanning/imaging systems (Accord, Accord Plus, Allegro Plus, Duet-3, Encore, DeNovo) and review workstations (Solo, Solo Touch, SoloWeb). The scanning systems range from semi-automated single-slide platforms to high-capacity 120-slide automated loaders, supporting FISH, Karyotype, and Circulating Tumor Cell analysis. The DeNovo is a dedicated CTC scanner for liquid biopsy applications. Review workstations enable local or remote analysis and reporting. Products are distributed internationally by Abbott Molecular and supported by dedicated AI-powered analysis applications for cytogenetics, pathology, and CTC workflows.
Differentiator
Problem solved
Functional benefit
Brands
- DeNovo: CTC (Circulating Tumor Cell) scanner system for automated detection, analysis and characterization of circulating tumor cells
- Solo
- Solo Touch
- SoloWeb
- Duet-3
- Encore
- Accord
- Accord Plus
- Allegro Plus
Products and services
- Accord Semi-automatic fluorescent imaging system with single slide manual stage and AI-based applications for scanning, analyzing and sorting FISH and Karyotype samples in real-time. FDA cleared and CE-IVDR compliant. Targets clinical and research cytogenetic laboratories.
- Accord Plus Automatic fluorescent imaging system with single slide motorized stage and AI-based applications for automated scanning, analysis, and sorting of FISH and Karyotype samples in real-time. Targets clinical cytogenetic laboratories.
- Allegro Plus Automatic imaging system with 8 slide motorized stage for batch scanning of multiple FISH and Karyotype sample types. AI-based applications enable fast and accurate identification of chromosomal aberrations under fluorescent light. Targets high-volume clinical cytogenetic and pathology laboratories.
- Duet-3 High throughput, fully automated imaging system accommodating multiple FDA cleared applications and CE-IVDR compliance. Supports FISH, Karyotype, Circulating Tumor Cells, and whole-slide virtualization. Targets hospital and reference laboratories requiring validated multi-application automation.
- Encore High capacity, compact and versatile automated fluorescent and bright-field imaging system with 60/120 slide loader, automated barcode reader, and automated oil dispenser. Supports walk-away automated scanning for clinical and research laboratories.
- DeNovo Fully automated benchtop scanning system specifically designed for detection, analysis, and characterization of circulating tumor cells (CTCs). Brings liquid biopsy to clinical routine with high automation, standardization, and sensitivity in an all-in-one scanner design. Supports any enrichment technique and marker combination. Targets oncology research and clinical labs.
- Solo Workstation Stand-alone offline workstation for review and analysis of test results away from the microscope. Includes advanced review and analysis tools, report generation, and archiving features for the entire BioView application portfolio. Targets clinical laboratory reviewers.
- Solo Touch Workstation Stand-alone workstation with integrated touch screen for intuitive review and analysis of FFPE tissue sections hybridized with FISH probes, with improved ergonomics and user experience. Targets pathology laboratories.
- SoloWeb TRUE web-based remote review and analysis workstation using standard web browsers from any location. Locally installed in the laboratory with embedded communication and management features for real-time remote review, analysis, and reporting. Targets multi-site hospital and reference lab networks.
- AI-Powered Karyotype Application Automated metaphase finding plus G and R band chromosome classification powered by AI and deep learning. Provides a comprehensive solution for cytogenetic laboratories performing karyotype analysis. Targets clinical cytogenetic laboratories.
Quantifiable outcome
- Improves accuracy compared to manual scoring
- +3 more outcomes
Companies that use BioView
Customer profileNamed customers5 records
Segments5 records
Ideal customer profiles4 records
BioView technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature8 records
BioView partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- ANGLE plccorePartnership to develop a liquid biopsy CTC HER2 assay for breast cancer, combining ANGLE's FDA-cleared Parsortix PC1 Clinical System for CTC harvesting with BioView's automated imaging systems for HER2 expression and gene amplification detection in CTCs. This addresses the HER2-low breast cancer market opportunity (55% of cases) for treatment with antibody-drug conjugates like ENHERTU.
- Capio BiosciencesminorCollaboration to develop an integrated workflow for sample-to-answer assay of circulating tumor cells, utilizing Capio's CapioCyte system and BioView's DeNovo system for detection and characterization of tumor cells from prostate cancer.
- RUBYnanomed (INL Spin-off)minorCollaboration with International Iberian Nanotechnology Laboratory (INL) spin-off RUBYnanomed to develop custom imaging solutions to accelerate deployment of CTC technology in clinical settings, funded by 'la Caixa' Foundation.
- AbnovaminorLaunch of integrated all-in-one imaging system with AI solution for identification of circulating tumor cells (CTCs) and circulating fetal cells (CFCs). Abnova has exclusive rights to commercialize the integrated system with their enrichment instruments. Systems sold in Japan, Taiwan, and China.
- Vortex BiosciencesminorCollaboration to develop integrated workflow for identifying clinical biomarkers on CTCs, combining Vortex's VTX-1 Liquid Biopsy System for CTC isolation with BioView's Duet imaging system for automated biomarker analysis including PD-L1 expression.
- Diagnostic SolutionsminorDistribution agreement for BioView's early detection lung cancer test (LCD test) in Australia and New Zealand. Diagnostic Solutions is part of Diploma Healthcare Group, traded in London.
- Abbott MolecularcoreAbbott Molecular serves as BioView's exclusive worldwide distributor for all products. The partnership includes joint development agreements where Abbott develops FISH probes for RUO and IVD purposes while BioView develops software and applications for automated imaging. Products are marketed and sold by Abbott in accordance with their distribution agreement.
- CITOGEMminorRegional distributor for BioView products in Brazil, located in Sao Paulo.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
BioView competitors and assessment
Company assessmentDirect peers
- MetaSystems: MetaSystems is a German company specializing in automated microscope systems for cytogenetics, with the Metafer platform for metaphase finding and FISH spot counting. It directly competes with BioView's Duet and Allegro Plus lines in hospital and reference cytogenetic laboratories globally.
Broad incumbents
- Leica Biosystems (Danaher): Leica Biosystems, part of Danaher's diagnostics platform, provides the CytoVision automated karyotyping and FISH imaging system as well as a much broader digital pathology portfolio. It overlaps with BioView in FISH/karyotype imaging but operates at significantly greater scale and with deeper pathology workflow integration.
- Carl Zeiss Microscopy: Zeiss is a global leader in research and clinical microscopy, including automated imaging platforms used in cytogenetics and pathology. While not a focused FISH competitor, its microscope and imaging technology stack overlaps with BioView's core hardware foundation and competes for the same hospital lab capital budgets.
- Hamamatsu Photonics: Hamamatsu supplies high-resolution digital camera and slide scanning systems used in pathology and cytogenetics labs, including the NanoZoomer whole-slide scanners. It competes with BioView in automated imaging for clinical labs and offers broader life science and diagnostics imaging capabilities.
- Olympus Life Science: Olympus provides automated microscopy and slide scanning platforms used in pathology and cytogenetics labs, including the VS200 and SLIDEVIEW systems. It competes for capital budgets in hospital labs that evaluate BioView's automated imaging solutions alongside broader microscope digitization initiatives.
Emerging players
- Menarini Silicon Biosystems: Menarini Silicon Biosystems offers the DEPArray and CELLSEARCH systems for CTC isolation and single-cell analysis. It directly competes with BioView's DeNovo platform in the liquid biopsy/CTC workflow and targets overlapping oncology research and clinical lab customers.
- ANGLE plc: ANGLE plc's FDA-cleared Parsortix PC1 Clinical System harvests CTCs from blood for downstream analysis and is partnered with BioView for HER2 detection in breast cancer. While ANGLE operates upstream in CTC enrichment, it is a comparable emerging liquid biopsy player targeting the same oncology lab workflow.
- RareCyte: RareCyte provides the AccuCyte CTC system and Orion imaging platform for circulating tumor cell identification and characterization. It competes with BioView's DeNovo in oncology research and clinical labs focused on liquid biopsy workflows and rare cell detection.
- CytoTrack: CytoTrack develops the CytoTrack CT4 scanner for high-throughput detection and characterization of circulating tumor cells without enrichment. It targets the same CTC imaging workflow as BioView's DeNovo, particularly for oncology research and pharma biomarker development.
- Epic Sciences: Epic Sciences provides liquid biopsy CTC analysis services and platforms focused on characterizing CTCs and ctDNA for oncology applications. It competes with BioView's DeNovo-based CTC offering for pharma biomarker development and clinical research customers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
BioView social profiles
Digital presenceBioView compliance and trust
Trust signalCompliance4 records
BioView financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioView leadership team
Management profileNumber of profiles
Profiles5 records
BioView subsidiaries and ownership
Company hierarchySubsidiaries1 record
BioView funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioView M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioView
What does BioView do?
BioView develops, manufactures, and markets automated cell imaging and analysis systems that combine motorized fluorescent and bright-field microscopes with high-resolution cameras and AI/deep learning software for FISH (fluorescence in situ hybridization), karyotype, and circulating tumor cell (CTC) analysis. The product line spans semi-automatic single-slide scanners (Accord), mid- to high-throughput multi-slide platforms (Allegro Plus, Duet-3, Encore), a dedicated CTC liquid biopsy scanner (DeNovo), and review workstations (Solo, Solo Touch, SoloWeb) used by clinical cytogenetic, pathology, oncology, and research laboratories worldwide.
Is BioView a public or private company?
BioView is a public company. It is classified as public and is currently operating.
When was BioView founded?
BioView was founded in 2000. It employs 11 to 50 people.
Where is BioView based?
BioView is headquartered in Billerica, United States, in the North America region.
How does BioView make money?
Four revenue lines are on record. Imaging System Hardware Sales are the primary driver. The others are software Applications, review Workstation Software and service and Support.
Who are BioView's main competitors?
MetaSystems is listed as a direct peer. Broad incumbents are Leica Biosystems (Danaher), Carl Zeiss Microscopy, Hamamatsu Photonics and Olympus Life Science. Emerging players are Menarini Silicon Biosystems, ANGLE plc, RareCyte, CytoTrack and Epic Sciences.
Does BioView have an API?
No public API is recorded for BioView.
What industry is BioView in?
BioView's product category is Automated Cell Imaging and Analysis Systems. Its primary akta.pro industry code is HLAGAIAE, Microscopy, Imaging & Flow Cytometry Instruments, with a secondary code of HLAHAAAF, Flow Cytometry & Cellular Analysis Diagnostics. Its NAICS code is 334516 and its SIC code is 3826.